Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital

Chardan Capital assumed coverage on shares of Stoke Therapeutics (NASDAQ:STOKFree Report) in a research report report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $24.00 price target on the stock.

STOK has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.29.

Read Our Latest Stock Analysis on Stoke Therapeutics

Stoke Therapeutics Stock Performance

Shares of STOK opened at $11.68 on Friday. The stock has a market capitalization of $618.65 million, a PE ratio of -5.56 and a beta of 0.95. The company’s 50-day simple moving average is $12.48 and its 200-day simple moving average is $13.55. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, sell-side analysts predict that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics during the second quarter valued at approximately $29,000. Nisa Investment Advisors LLC raised its stake in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Stoke Therapeutics in the 2nd quarter valued at $123,000. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at $160,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the last quarter.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Read More

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.